600557.SH
康缘药业
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 11.91
−1.24%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 3.2B | 3.3B | 3.9B | 4.9B | 4.4B |
| Cost of Revenue | 921.8M | 940.3M | 1.0B | 1.3B | 1.2B |
| Gross Profit | 2.3B | 2.4B | 2.9B | 3.6B | 3.1B |
| Operating Expenses | |||||
| R&D Expense | 604.6M | 607.6M | 638.1M | 847.0M | 605.7M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 316.1M | 316.5M | 318.2M | 349.7M | 189.6M |
| Selling & Marketing Expense | 1.1B | 1.1B | 1.5B | 1.9B | 1.9B |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 2.1B | 2.1B | 2.6B | 3.2B | 2.7B |
| Cost and Expenses | 3.0B | 3.0B | 3.6B | 4.5B | 3.9B |
| Operating Income (EBIT) | 362.8M | 370.4M | 384.5M | 460.8M | 454.8M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 350.4M | 356.6M | 384.8M | 448.0M | 445.7M |
| Income Tax Expense | 48.5M | 49.3M | 3.8M | 3.9M | 3.8M |
| Bottom Line | |||||
| Net Income | 299.8M | 303.9M | 391.9M | 464.2M | 434.5M |
| Earnings from Cont. Ops | 301.9M | 307.3M | 380.9M | 444.1M | 441.9M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 299.8M | 303.9M | 391.9M | 464.2M | 434.5M |
| Per Share | |||||
| Basic EPS | CN¥0.53 | CN¥0.54 | CN¥0.68 | CN¥0.81 | CN¥0.75 |
| Diluted EPS | CN¥0.53 | CN¥0.54 | CN¥0.68 | CN¥0.80 | CN¥0.75 |
| Revenue Per Share | CN¥5.73 | CN¥5.85 | CN¥6.76 | CN¥8.49 | CN¥7.51 |
| Shares | |||||
| Basic Shares Outstanding | 566.3M | 562.8M | 576.3M | 573.0M | 579.3M |
| Diluted Shares Outstanding | 566.3M | 562.8M | 576.3M | 573.0M | 579.3M |
| Profitability Metrics | |||||
| EBITDA | — | 569.0M | 589.3M | 661.4M | 648.3M |
| D&A | — | 198.5M | 204.8M | 200.6M | 193.5M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026